Categories
- Machine Tools: Cutting (3,917)
- Machine Tools: Metalforming, shearing, folding and punching (1,481)
- Machine Tools: moulding (1,058)
- Cutting tools (1,766)
- Welding and Joining (1,488)
- Finishing, preparation, coating and painting (1,025)
- Automation and assembly systems (1,044)
- Manufacturing support (8,593)
- Industry news, commerce, exhibitions, education (8,185)
- Packaging (2,865)
- Specialist Manufacturing Sectors and Metals Producing (1,318)
- Books, CDs and Videos (189)
- IT for manufacturing management and production (3,425)
- IT for engineering, industrial and commercial applications (4,837)
- Manufacturing IT hardware and communications (1,569)
- Used machinery and machine tools (29)
- Materials handling and storage (912)
- Wood and non-metallics working (73)
- Metrology instruments and systems (3,798)
- Testing and quality control systems and services (4,939)
- Subcontracting services (1,142)
LGC Launches ADME-Tox Screening Service
A
LGC product story
Edited by the Manufacturingtalk editorial team
Mar 10, 2003
Bioanalytical services at LGC's new ADME-Tox laboratory include in vitro drug metabolism, cellular toxicology and prediction of gastrointestinal transport.
Bioanalytical services at LGC's new ADME-Tox laboratory include in vitro drug metabolism, cellular toxicology and prediction of gastrointestinal transport.
LGC, the UK's leading independent analytical laboratory, is expanding its bioanalytical services for pharmaceutical and drug discovery companies with the introduction of in vitro ADME-Tox (Absorption, Distribution, Metabolism, Excretion - Toxicology) screening in new facilities at Teddington.
LGC's new range of ADME-Tox screening services, which together are able to filter out library compounds with poor pharmacokinetic profiles, include Caco-2 permeability, in vitro metabolism, plasma stability, cellular toxicology and plasma protein binding.
Dr John Marriott, Director of Analytical Technology at LGC and Government Chemist, said: "In vitro ADME-Tox screening is now an integral part of the pharmaceutical industry's overall strategy to reduce the attrition rate in bringing drugs to market - the 'fail early, fail cheaply' paradigm.
LGC is working with pharmaceutical companies looking to outsource services to achieve the best cost-effectiveness, and discovery and combinatorial companies wanting to have their lead compounds screened." ADME-Tox screening is the latest in a series of services LGC now supplies to the pharmaceutical sector.
Companies have the option to integrate the new service with others already established - from proteomic and genomic analyses, to tandem LC-MS-MS method development and validation - and have access to LGC's Runcorn facility, which is equipped with specialist instrumentation to support a variety of pharmaceutical applications.
Niall Martin, Head of Drug Discovery at KuDOS Pharmaceuticals Limited, said: "We have used LGC's ADME-Tox service and are extremely happy with the quality and speed of the work.
As a small pharmaceutical company, it's important that we have flexibility in the models and LGC have proven excellent in generating the results we need for our drug discovery programmes." Dr Richard Worswick, LGC's Chief Executive, said: "At LGC, we are committed to good bioanalytical practice to improve analytical data and results for the pharmaceutical industry.
One project we lead under the DTI's Measurements for Biotechnology programme is to enable in vitro hepatocyte-based measurements for drug metabolism and hepatoxicity to be compared.
We hold exclusive commercialisation rights to the patented diagnosis of the CYP2D6 'poor metaboliser' gene variation and, trading as LGC Promochem, we supply pharmaceutical, clinical, biomaterial and other reference substances across Europe.".
Not what you're looking for? Search the site.
Contact LGC
Related Stories
